Drug Type Biological products |
Synonyms BMS 986315 |
Target |
Mechanism NKG2A antagonists(killer cell lectin like receptor C1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization ![]() |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 2 | US | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | AR | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | AU | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | CL | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | FR | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | IT | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | PL | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | RO | 27 Nov 2023 | |
Non-Small Cell Lung Cancer | Phase 2 | ES | 27 Nov 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 14 Jul 2020 |